TREATMENT OF VERNAL KERATOCONJUNCTIVITIS WITH DICLOFENAC SODIUM EYE DROPS 0.1%
|Full paper||Not Available|
Twenty seven patients having bilateral active vernal keratocordunctivitis (VKC): 5 mild (all palpebral), 14 moderate (9 palpebral and 5 mixed) and 5 severe (all mixed) were treated with a new non-steroidal anti-inflammatory eye drops (Diclofenac Sodium 0.1%) for 4 weeks. Two patients did not complete treatment All symptoms disappeared in mild cases except itching in one patient. Total score of foreign-body sensation was markedly reduced in moderate and severe cases (92% and 75% respectively), while total score of photophobia showed the least decrease in both groups (63.6% and 58.33% respectively). Conjunctival hyperaemia and discharge disappeared in all mild cases with treatment. The greatest decrease in total score of clinical signs was in conjunctival hyperaemia for moderate cases (90.9%) and in conjunctival • discharge for severe cases(7096). While the least decrease was in superficial punctate keratitis (SPK) (46.6% and 33.33% in moderate and severe ▪ cases respectively). In all cocPs tarsal papillae did not disappear but became less hyperaemic and slightly smaller in size. Diclofenac Sodium eye drops 0.1% could be considered an additional tool in treatment of VKC as it showed efficacy in managing most of symptoms and signs. Its action is similar to systemic non-steroidal antiinflammatory drugs (NSAIDS) without having their side effects.